拜耳將發表關於心臟與腎臟疾病治療的最新臨床數據
Bayer to present new clinical data on heart and kidney disease treatments
Updated at: August 29, 2026 at 04:30 AM
拜耳公司透過全新的「精準心臟病學」戰略，正重塑現代醫學的面貌。
Bayer is reshaping the landscape of modern medicine with its new focus on "precision cardiology."
該公司不再將心臟與腎臟疾病視為孤立的病症，而是轉而瞄準相互關聯的「心血管-腎臟-代謝」(CKM)路徑。
Moving away from treating heart and kidney conditions as isolated issues, the company is targeting the interconnected "cardiovascular-kidney-metabolic" (CKM) pathways.
在近期舉行的2026年歐洲心臟病學會年會上，拜耳強調了其旗艦藥物非奈利酮(finerenone，商品名KERENDIA)取得的重大進展。
At the recent European Society of Cardiology Congress 2026, Bayer highlighted significant progress with its flagship drug, finerenone (KERENDIA).
來自FIND-CKD試驗與大規模INFINITY分析的數據顯示，非奈利酮能有效降低各類患者群體出現腎衰竭與心血管事件的風險。
Data from the FIND-CKD trial and the large-scale INFINITY analysis demonstrated that finerenone effectively reduces the risk of kidney failure and cardiovascular events, such as heart failure hospitalizations, across diverse patient groups.
除了非奈利酮之外，拜耳亦持續擴展產品組合，納入諸如用於診斷心臟澱粉樣變性的PET放射性示蹤劑等創新工具，並針對中風預防進行持續研究。
Beyond finerenone, Bayer is broadening its portfolio to include innovative tools like PET radiotracers for cardiac amyloidosis and ongoing research into stroke prevention.
透過與范德比大學(Vanderbilt University)醫學中心等機構合作，拜耳旨在加速研發能及早介入以保護患者健康的治療方案。
By collaborating with institutions like Vanderbilt University Medical Center, Bayer aims to accelerate the discovery of therapies that intervene early to protect patient health.
隨著醫學界轉向全面且聚焦CKM的照護，拜耳的策略發展反映了慢性病管理的重要演進，即優先考量長期預防，而非單純處理症狀。
As the medical community shifts toward holistic, CKM-focused care, Bayer’s strategic developments reflect a critical evolution in how we manage chronic disease, prioritizing long-term prevention over simple symptom management.
